Novo Nordisk said Monday that a real-world study found adults with type 2 diabetes who stayed on an escalated dose of Ozempic had a lower risk of major cardiovascular events than those who switched to Eli Lilly's Mounjaro. Where did the announcement land? In a litigation filing, which is an odd home for a heart study, since the two companies are currently fighting over marketing claims. You can read the Reuters coverage here.

Before anyone rushes to call their pharmacist, the caveats. I've only read the coverage, not the full analysis, and real-world studies are a different animal from randomized trials. In a randomized trial, researchers assign patients by chance and control the comparison. In a real-world study, they look back at what actually happened to patients in insurance databases and electronic health records, which means the two groups may differ in important ways. People who switch drugs mid-treatment usually switch for a reason. Side effects, maybe. Poor response, maybe cost. That alone can skew a comparison.

The question the study asks is still a genuinely important one. Both Ozempic (semaglutide) and Mounjaro (tirzepatide) belong to the GLP-1 family of medications, though tirzepatide also targets a second gut hormone called GIP. Semaglutide has the longer cardiovascular track record, with years of outcome data behind it, and that evidence is part of why cardiologists got comfortable prescribing these drugs beyond blood sugar control. Tirzepatide is arguably more powerful for weight loss and glucose control, but its heart-outcome data is newer territory.

A head-to-head look at actual cardiovascular events between the two drugs answers something patients ask me about constantly, the same way patients used to ask which statin was "better." For years the honest answer was that the best drug is the one you take consistently.

That framing matters here too. A whole line of adherence research shows that taking any medication consistently does quiet, meaningful work in reducing cardiovascular risk, regardless of which specific pill you're on. And adherence shapes these analyses in ways people don't always appreciate. If the patients who switched to Mounjaro were already struggling with their regimen, or had different baseline heart risk, some of the difference Novo is highlighting could reflect the patients rather than the molecules. We won't know until independent researchers can examine the methods, how the groups were matched, and what confounders were adjusted for.

Then there's the context. This data surfaced through legal channels, in a dispute between two companies battling for market share in the most lucrative drug category on earth. I don't think that automatically makes the findings wrong, company-sponsored research can be rigorous, but the timing and framing serve a courtroom as much as a clinic. When my son Linton was sorting through competing health claims in his twenties I used to tell him: follow the data, but notice who's holding the microphone. Still good advice.

If you have type 2 diabetes and you're doing well on either medication, this is not a reason to switch or to worry. If you have existing cardiovascular disease, it's a reasonable thing to raise with your prescriber at your next visit, alongside the conversations you should already be having about blood pressure, cholesterol, and whether you're actually refilling on schedule.

I'll be watching for the full study, and if it gets published in a peer-reviewed journal I'll read it and tell you whether the numbers hold up. I've said before that I don't run with headline figures until I've seen the effect sizes and the methods, and a courtroom exhibit gets even more of my caution. But the question is worth asking. Someone was going to ask it eventually.